AU2335195A - Method of attenuating lung capillary leak in a mammal - Google Patents

Method of attenuating lung capillary leak in a mammal

Info

Publication number
AU2335195A
AU2335195A AU23351/95A AU2335195A AU2335195A AU 2335195 A AU2335195 A AU 2335195A AU 23351/95 A AU23351/95 A AU 23351/95A AU 2335195 A AU2335195 A AU 2335195A AU 2335195 A AU2335195 A AU 2335195A
Authority
AU
Australia
Prior art keywords
mammal
capillary leak
lung capillary
attenuating
attenuating lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU23351/95A
Other languages
English (en)
Inventor
Suresh S. Kerwar
Michael M. Wick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of AU2335195A publication Critical patent/AU2335195A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU23351/95A 1994-07-01 1995-06-29 Method of attenuating lung capillary leak in a mammal Abandoned AU2335195A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US269702 1994-07-01
US08/269,702 US5593671A (en) 1994-07-01 1994-07-01 Method of attenuating lung capillary leak in a mammal

Publications (1)

Publication Number Publication Date
AU2335195A true AU2335195A (en) 1996-01-18

Family

ID=23028336

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23351/95A Abandoned AU2335195A (en) 1994-07-01 1995-06-29 Method of attenuating lung capillary leak in a mammal

Country Status (9)

Country Link
US (1) US5593671A (enExample)
EP (1) EP0692251A1 (enExample)
JP (1) JPH0826998A (enExample)
KR (1) KR960003728A (enExample)
AU (1) AU2335195A (enExample)
CA (1) CA2152981A1 (enExample)
HU (1) HUT74245A (enExample)
NZ (1) NZ272476A (enExample)
TW (1) TW294596B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1115397B1 (en) 1998-08-28 2006-05-24 Intarcia Therapeutics, Inc. Compositions for mitigating the adverse effects of interleukin-2
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
AU2001283191A1 (en) * 2000-08-10 2002-02-25 Uab Research Foundation Compositions containing an inhibitor of dihydrofolate reductase and a folate
AU2005227263A1 (en) * 2004-03-05 2005-10-06 Novartis Vaccines And Diagnostics, Inc. In vitro test system for predicting patient tolerability of therapeutic agents
DE102006033837A1 (de) 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK86988A (da) * 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf

Also Published As

Publication number Publication date
JPH0826998A (ja) 1996-01-30
KR960003728A (ko) 1996-02-23
TW294596B (enExample) 1997-01-01
NZ272476A (en) 1997-06-24
HU9501980D0 (en) 1995-08-28
EP0692251A1 (en) 1996-01-17
CA2152981A1 (en) 1996-01-02
HUT74245A (en) 1996-11-28
US5593671A (en) 1997-01-14

Similar Documents

Publication Publication Date Title
AU2949595A (en) Improved valve and method and apparatus for assembling
IL140726A0 (en) Small inlet optical panel and a method of making a small inlet optical panel
GB9613615D0 (en) Method of manufacturing a noise attenuation panel
AU4605596A (en) Power steering attenuation hose construction and method of making the same
AU3229395A (en) Test method
AU3101795A (en) Method of making a benzylpropanamine
AU5508998A (en) Seismic semblance/discontinuity method
AU1278495A (en) Spectacles and method for making same
AU2335195A (en) Method of attenuating lung capillary leak in a mammal
AU685004B2 (en) Pipe connecting method and pipe structure
AU684975B2 (en) Tension-resisting pipe connection and method of making same
AU2799195A (en) A method of creating an effect
AU2919995A (en) A compound toothpast and the method of making it
GB2330217B (en) Polarisng panel and method for making same
AU634283B2 (en) Agent for determining manganese and method relating thereto
AU1783195A (en) Multiple level occulting using a mask buffer
AU2950395A (en) Fungus extraction method and kit
AUPM913294A0 (en) Animation method and device
AU2947695A (en) Frosted terry cloth and method for producing same
AU2757795A (en) A capsule-stiffening arrangement and a method for its manufacture
AU1907395A (en) Capillary tube and methods for producing said tube
GB9514057D0 (en) Models and kits
AU3158995A (en) Composite pipe and fabrication method
AU1622795A (en) Concrete pipe manufacture and methods
AU9164098A (en) Method and equipment for attenuating sound in a duct